Tesamorelin

TESAMORELIN
Targeted Support for the Growth Hormone Pathway
Tesamorelin is an advanced peptide analogue of growth hormone-releasing factor (GRF), designed to stimulate the body’s natural growth hormone pathway.
By activating GRF receptors, Tesamorelin encourages the pituitary gland to release growth hormone, which can subsequently increase circulating IGF-1 levels. This pathway has been extensively studied in relation to visceral adipose tissue — the deeper abdominal fat stored around the organs.
WHAT MAKES TESAMORELIN DIFFERENT?
Rather than supplying growth hormone directly, Tesamorelin works upstream, encouraging the body to increase its own growth hormone release.
Research has demonstrated reductions in visceral abdominal adipose tissue in specific clinical populations, particularly adults with HIV-associated lipodystrophy.
KEY AREAS OF INTEREST
• Growth Hormone Pathway
Stimulates the body’s natural growth hormone-releasing mechanism.
• IGF-1 Support
Promotes increased circulating IGF-1 as part of the GH/IGF-1 pathway.
• Visceral Fat
Has been clinically studied for its ability to reduce excess visceral abdominal adipose tissue in its approved indication.
• Targeted Mechanism
Works through the body’s own GRF signalling pathway rather than directly administering growth hormone.
THE SCIENCE BEHIND THE PEPTIDE
Tesamorelin represents a targeted approach to modulating the GH–IGF-1 axis, making it a peptide of significant interest in metabolic and body-composition research.
Its mechanism is specifically focused on visceral adipose tissue and growth-hormone signalling, rather than simply reducing overall body weight.